Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ADC

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

- PMLiVE

Abbott and Seattle expand antibody-drug conjugate collaboration

Pharma company could pay $220m per oncology target

Bayer’s former oncology head Robert Rosen joins AP Pharma

Will lead launch of drug to prevent chemotherapy-induced nausea

- PMLiVE

Lilly’s gastric cancer prospect clears phase III trial

Ramucirumab improved both overall and progress-free survival

Roche - Basel

Roche Q3 sales up on cancer drugs

And CEO Schwan commits to gene sequencing despite failed Illumina bid

Celgene’s Abraxane receives FDA approval in lung cancer

Adds to current breast cancer indication

AZ’s MedImmune partners with global cancer institutes

Will research combinations of immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links